County-Level Opioid Prescribing in the United States, 2015 and 2017
In the United States in 2016, prescription opioids accounted for 40% of the 42 249 opioid-related overdose deaths. 1 Although the number of opioid prescriptions has been declining over the past several years, prescribing remains elevated relative to 1999 levels. 2 This study examines opioid prescribing at the national and county levels in 2015 and 2017.
Methods | Data come from IQVIA's Xponent database, which contains prescriptions dispensed from approximately 50 400 retail pharmacies, representing 90% of prescriptions in the United States. Opioid prescribing at the national and county levels were analyzed for 2015 and 2017. Measures included overall opioid prescribing rates, high-dose prescribing rates, morphine milligram equivalent (MME) per capita, average daily MME per prescription, and average and median prescription duration. The MME was calculated using published ratios. 3 To compute MME per capita, total MME was divided by population estimates. Prescribing rates were calculated per 100 persons. Annual population estimates were obtained from the US Census Bureau and included individuals of all ages. High-dose prescriptions were defined as those resulting in 90 or more MME per day. Cough and cold formulations containing opioids and buprenorphine products typically used for opioid-use disorder were excluded. Countylevel opioid prescribing was examined by quartile. All analyses were performed in Stata, version 14.2 (StataCorp). The Centers for Disease Control and Prevention determined this study to be exempt from human-subject regulations and institutional review board approval.
Results | From 2015 to 2017, the amount of opioids prescribed in the United States decreased 20.1%, from 641.4 to 512.6 MME per capita; opioid prescribing rates decreased 16.9%, from 70.7 to 58.7 per 100 persons; high-dose prescribing rates decreased 25.3%, from 6.7 to 5.0 per 100 persons; and the average daily MME per prescription decreased 6.0%, from 48.1 to 45.2 MME (Table) . Meanwhile, average and median duration of opioid prescriptions increased by 3.4% (17.7 to 18.3 days) and 33.3% (15.0 to 20.0 days), respectively. In 2017, the amount of opioids prescribed per capita varied substantially at the county level (Figure and Supplement). The average amount of opioids prescribed in the highest quartile (1061.0 MME per capita) was 5.8 times the amount in the lowest quartile (182.8 MME per capita) (Table) . Substantial variation between the highest and lowest prescribing counties was also observed for overall prescribing rates (4.6 times higher) and high-dose prescribing rates (7.1 times higher). Abbreviation: MME, morphine milligram equivalent. a Quartiles were created using MME per capita to characterize the distribution of opioids prescribed. b Among the 2949 counties with available data in 2015 and 2017, changes of Ն10% were considered to represent an increase or decrease, whereas changes <10% were considered stable. c Prescribing rates are presented per 100 persons.
d High-dose prescribing rate includes opioid prescriptions with daily dosage Ն90 MME.
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Letters Discussion | The reduction in opioid prescribing that began in 2012 has accelerated in the United States. The amount of opioids prescribed decreased an average of 10.0% annually with reductions in 74.7% of counties from 2015 to 2017, compared with 3.6% annually with reductions in 49.6% of counties from 2010 to 2015. 2 However, opioids continued to be prescribed at 512.6 MME per capita in 2017, nearly triple the amount prescribed in 1999. 2 The duration of opioid prescriptions continues to increase nationally, likely because of greater decreases in shorterterm opioid prescriptions (<30 days) than in longer-term prescriptions.
2 Average duration remained stable in 89. manufactured fentayl. 1 The opioid overdose epidemic is a complex crisis requiring coordination across multiple sectors, including public health, health care, and public safety. Limitations of this study include the inability to determine the appropriateness of opioid prescriptions, lack of data on prescriptions dispensed outside of retail pharmacies (ie, mail-order, prescriber-dispensed, and hospital-or clinicbased pharmacies), and the reliance on where the prescription was dispensed, rather than where it was prescribed or used. Nonetheless, this study provides national-and countylevel information on opioid prescribing to help inform efforts in improving opioid prescribing in the United States. 3 Recent national data suggest changing patterns of overdose among specific populations and age cohorts, including increases in opioid and cocaine deaths among blacks. 4 Although the overall number of opioid analgesic deaths has plateaued, overdose death rates continue to increase among younger and middle-aged whites. 5 We examined 2017 New York City data on overdose deaths to determine patterns related to age, race, and drug type.
Methods | We obtained death certificate data from the New York City Office of Vital Statistics and toxicology files from the New York City Office of the Chief Medical Examiner (OCME). Deaths were defined as overdose if the OCME determined an accidental manner of death and assigned the underlying or multiple cause of death an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) code of X40 through X44, F11 through F16, or F18 or F19 (excluding F-codes with 0.2 or 0.6 third digit, which are not specific to drug overdose). Drug-involvement classifications were based on postmortem toxicology testing. Race and ancestry are collected separately on the death certificate. Following National Century for Health Statistics Guidelines, responses were recoded into 1 of the following 4 race/ethnicity categories: nonHispanic white, non-Hispanic black, Latino, and undefined/ other. We calculated numbers of deaths, age-adjusted rates per 100 000 people, and standard errors, and compared drugspecific overdose death rates by age and race. We adjusted data for age using 2000 United States standard and New York City population estimates, modified from United States Census Bureau intercensal population estimates for 2016, as updated in September 2017. We constructed 95% confidence intervals (CIs) for age-specific rates using the normal distribution when there were 100 or more events; we used the Poisson distribution when there were fewer than 100 events. Nonoverlapping CIs were considered statistically significant. Note that this report includes only deaths for which the OCME determined the cause of death at the time of data analysis. Because it can take some time for OCME to complete investigations of suspected overdose deaths, some cases for 2017 were still pending final determination, and so those data are provisional. All analysis took place between August 8 and October 24, 2018.
Results | In 2017, there were 1487 overdose deaths in New York City: 556 (37.0%) among whites, 421 (28.0%) among blacks, 455 (31.0%) among Latinos, and 55 (4.0%) among other or undeRelated article pages 469 and 574
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Letters fined racial/ethnic groups (Table) . Among younger persons (age 15-34 years), heroin and/or fentanyl overdose death rates per 100 000 New Yorkers were higher among whites (22.2; 95% CI, 19.0-25.5) than blacks (5.8; 95% CI, 4.0-8.2) or Latinos (9.7; 95% CI, 7.6-12.1). Conversely, heroin and/or fentanyl overdose death rates among older persons (age 55-84 years) were higher among blacks (25.4; 95% CI, 20.9-30.0) than whites (9.4; 95% CI, 7.3-11.8) (Figure) . Older blacks had significantly higher cocaine overdose death rates (25.4; 95% CI, 20.9-30.0) than whites (5.1; 95% CI, 3.6-7.0) and Latinos (11.8; 95% CI, 8.9-15.4). Discussion | Our findings suggest the existence of 2 concurrent opioid overdose epidemics in New York City. Overdose death rates for blacks and Latinos were highest among middle-aged and older persons; overdose death rates for whites were highest among middle-aged and younger persons. Recent research found that older blacks and Latinos at risk of overdose were more likely than whites to have long drug trajectories (spanning the heroin epidemics of the 1970s and 1990s and the human immunodeficiency virus/AIDS epidemic), to be primary heroin users, and to have histories of opioid agonist treatment. 5 In contrast, middle-aged and younger whites were more likely to have shorter drug trajectories starting after 2000, to be primary opioid analgesic users who transitioned to heroin, and to be less likely to have histories of opioid agonist treatment. 5, 6 The distinct age distribution and drug involvement of overdose deaths among New York City blacks, Latinos, and whites, along with complementary evidence about drug use trajectories, highlight the need for heterogeneous approaches to treatment and the equitable allocation of treatment and health care resources to reach diverse populations at risk of overdose.
